Koblan KS - Search Results

1

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. Koblan KS, et al. N Engl J Med. 2020 Apr 16;382(16):1497-1506. doi: 10.1056/NEJMoa1911772. N Engl J Med. 2020. PMID: 32294346 Clinical Trial.

2

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM).

Hopkins SC, Ogirala A, Loebel A, Koblan KS. Hopkins SC, et al. Among authors: koblan ks. Psychiatry Res. 2020 Dec;294:113569. doi: 10.1016/j.psychres.2020.113569. Epub 2020 Nov 11. Psychiatry Res. 2020. PMID: 33223272 Free article. Clinical Trial.

3

Effect of TAAR1/5-HT_1A agonist SEP-363856 on REM sleep in humans.

Hopkins SC, Dedic N, Koblan KS. Hopkins SC, et al. Among authors: koblan ks. Transl Psychiatry. 2021 Apr 20;11(1):228. doi: 10.1038/s41398-021-01331-9. Transl Psychiatry. 2021. PMID: 33879769 Free PMC article. Clinical Trial.

4

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.

Hopkins SC, Wilkinson S, Corriveau TJ, Nishikawa H, Nakamichi K, Loebel A, Koblan KS. Hopkins SC, et al. Among authors: koblan ks. Clin Pharmacol Ther. 2021 Sep;110(3):808-815. doi: 10.1002/cpt.2282. Epub 2021 Jun 12. Clin Pharmacol Ther. 2021. PMID: 33961287 Free PMC article. Clinical Trial.

5

[No title available]

[No authors listed] [No authors listed] PMID: 34127116

6

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.

Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, Koblan KS. Galluppi GR, et al. Among authors: koblan ks. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1245-1254. doi: 10.1002/psp4.12692. Epub 2021 Aug 10. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34292664 Free PMC article.

7

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.

Loebel A, Koblan KS, Tsai J, Deng L, Fava M, Kent J, Hopkins SC. Loebel A, et al. Among authors: koblan ks. J Affect Disord. 2022 Jan 1;296:549-558. doi: 10.1016/j.jad.2021.09.109. Epub 2021 Oct 3. J Affect Disord. 2022. PMID: 34614447 Free article. Clinical Trial.

8

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.

Hopkins SC, Ogirala A, Worden M, Koblan KS. Hopkins SC, et al. Among authors: koblan ks. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. Clin Drug Investig. 2021. PMID: 34751928 Free PMC article. Clinical Trial.

9

Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.

Hopkins SC, Reasner DS, Koblan KS. Hopkins SC, et al. Among authors: koblan ks. Psychiatry Res. 2013 Aug 15;208(3):285-7. doi: 10.1016/j.psychres.2013.04.021. Epub 2013 May 24. Psychiatry Res. 2013. PMID: 23706899 Clinical Trial.

10

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.

Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, Loebel A. Koblan KS, et al. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. doi: 10.1038/npp.2015.124. Epub 2015 May 7. Neuropsychopharmacology. 2015. PMID: 25948101 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page